Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: Rescue of the template bleeding time in a single-center prospective study

Thrombosis Journal

Volumn 10, Issue , 2012, Pages

  Altman, Raul ^a   Rivas, Ana J ^a   Gonzalez, Claudio D ^b,c  

^a Centro de Trombosis de Buenos Aires   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c FAVALORO UNIVERSITY   (Argentina)

Author keywords

Bleeding time; Inhibition of platelet aggregation; Ipa; Nuisance bleeding; Platelet

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; ADENOSINE DIPHOSPHATE; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANXIOLYTIC AGENT; ARACHIDONIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FOLIC ACID; LEVOTHYROXINE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING TENDENCY; BLEEDING TIME; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EPISTAXIS; FEMALE; HEMATURIA; HUMAN; HYPERTENSION; LIGHT SCATTERING; LIGHT TRANSMISSION AGGREGOMETRY; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RECTUM HEMORRHAGE; RISK FACTOR; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM;

EID: 84855583721     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-10-3     Document Type: Article

References (44)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
2. Santa-Cruz RA, Steinhubl SR. Clopidogrel: how good is it and how does it work?. Curr Cardiol Rep 2004, 6:264-268. 10.1007/s11886-004-0074-z, 15182601.
3. Altman R, Luciardi HL, Muntaner J, Herrera RN. The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?. Thromb J 2004, 2:1. 10.1186/1477-9560-2-1, 331420, 14723795.
4. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. J Am Coll Cardiol 2007, 49:657-666. 10.1016/j.jacc.2006.10.050, 17291930.
5. Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B, Buonamici P, Gensini GF, Abbate R, Antoniucci D. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011, 306:1215-1223. 10.1001/jama.2011.1332, 21934054.
6. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003, 41:961-965. 10.1016/S0735-1097(02)03014-0, 12651041.
7. Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, Schömig A, von Beckerath N, Kastrati A. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010, 8:250-256. 10.1111/j.1538-7836.2009.03709.x, 19943882.
8. Shehab N, Sperling LS, Kegler SR, Budnitz DS. National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. Arch Intern Med 2010, 170:1926-1933. 10.1001/archinternmed.2010.407, 21098354.
9. Ben-Dor I, Torguson R, Scheinowitz M, Li Y, Delhaye C, Wakabayashi K, Maluenda G, Syed AI, Collins SD, Gonzalez MA, Gaglia MA, Xue Z, Kaneshige K, Satler LF, Suddath WO, Kent KM, Pichard AD, Waksman R. Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. Am Heart J 2010, 159:871-875. 10.1016/j.ahj.2010.01.016, 20435198.
10. Tantry US, Kereiakes DJ, Gurbel PA. Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. JACC Cardiovasc Interv 2011, 4:365-380. 10.1016/j.jcin.2010.12.009, 21511216.
11. Mehta A, Mehta D, Loganathan J, Paladugu N, Bhalodkar NC. Clopidogrel with proton pump inhibitors: safe or not?. Clin Cardiol 2011, 34:528-531. 10.1002/clc.20928, 21717475.
12. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction?. Am J Gastroenterol 2010, 105:34-41. 10.1038/ajg.2009.638, 19904241.
13. Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, Lardoux H, Coste P, Lefèvre T, Drouet E, Mulak G, Bataille V, Ferrières J, Verstuyft C, Danchin N. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation 2011, 123:474-482. 10.1161/CIRCULATIONAHA.110.965640, 21262992.
14. Zafar MU, Ibáñez B, Choi BG, Vorchheimer DA, Piñero A, Jin X, Sharma RK, Badimon JJ. A new oral antiplatelet agent with potent antithrombotic properties: Comparison of DZ-697b with clopidogrel in a randomised phase-I study. Thromb Haemost 2010, 103:205-212.
15. Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 2000, 129:1439-1436. 10.1038/sj.bjp.0703237, 1571986, 10742300.
16. Matsushima N, Jakubowski JA, Asai F, Naganuma H, Brandt JT, Hirota T, Freestone S, Winters KJ. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans. Platelets 2006, 17:218-226. 10.1080/09537100600565510, 16769599.
17. Asai F, Jakubowski JA, Naganuma H, Brandt JT, Matsushima N, Hirota T, Freestone S, Winters KJ. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans. Platelets 2006, 17:209-217. 10.1080/09537100600565551, 16769598.
18. Jakubowski JA, Matsushima N, Asai F, Naganuma H, Brandt JT, Hirota T, Freestone S, Winters KJ. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y(12) inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 2007, 63:421-430. 10.1111/j.1365-2125.2006.02792.x, 2203227, 17076696.
19. Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 2003, 38:710-713. 10.1016/S0741-5214(03)01029-2, 14560218.
20. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten Berg JM. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010, 303:754-762. 10.1001/jama.2010.181, 20179285.
21. Cattaneo M. Aspirin and clopidogrel efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004, 24:1980-1987. 10.1161/01.ATV.0000145980.39477.a9, 15388526.
22. Gurbel SP, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease. The ONSET/OFFSET Study. Circulation 2009, 120:2577-2585. 10.1161/CIRCULATIONAHA.109.912550, 19923168.
23. Antonino MJ, Mahla E, Bliden KP, Tantry US, Gurbel PA. Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. Am J Cardiol 2009, 103:1546-1550. 10.1016/j.amjcard.2009.01.367, 19463513.
24. Gremmel T, Steiner S, Seldinger D, Koppensteiner R, Panzer S, Kopp CW. Comparison of methods to evaluates clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009, 101:333-339.
25. Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antoniucci D, Gensini GF, Abbate R, Prisco D. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007, 5:1839-1847. 10.1111/j.1538-7836.2007.02656.x, 17723123.
26. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA, . Working Group on High On-Treatment Platelet Reactivity Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010, 56:919-933. 10.1016/j.jacc.2010.04.047, 20828644, Working Group on High On-Treatment Platelet Reactivity.
27. Tsukahara K, Kimura K, Morita S, Ebina T, Kosuge M, Hibi K, Okuda J, Iwahashi N, Maejima N, Nakachi T, Ohtsuka F, Hashiba K, Tahara Y, Sugano T, Umemura S. Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. Circ J 2010, 74:679-685. 10.1253/circj.CJ-09-0601, 20173303.
28. Serebruany V, Rao SV, Silva MA, Donovan JL, Kannan AO, Makarov L, Goto S, Atar D. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J 2010, 31:227-235. 10.1093/eurheartj/ehp434, 19854728.
29. Cuisset T, Cayla G, Frere C, Quilici J, Poyet R, Gaborit B, Bali L, Morange PE, Alessi MC, Bonnet JL. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?. EuroIntervention 2009, 5:325-329. 10.4244/51, 19736156.
30. Harrison P, Keeling D. Clinical tests of platelet function. Platelets 2006, 445-474. San Diego, CA: Elsevier/Academic Press, Michelson AD, 2.
31. Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007, 28:1702-1708. 10.1093/eurheartj/ehm226, 17569678.
32. Harrison P, Frelinger AL, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007, 120:323-336. 10.1016/j.thromres.2006.11.012, 17239428.
33. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. J Am Coll Cardiol 2007, 49:657-666. 10.1016/j.jacc.2006.10.050, 17291930.
34. Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004, 109:3171-3175. 10.1161/01.CIR.0000130846.46168.03, 15184279.
35. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003, 41:961-965. 10.1016/S0735-1097(02)03014-0, 12651041.
36. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, Mahaffey KW, Califf RM, Harrington RA. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005, 96:1200-1206. 10.1016/j.amjcard.2005.06.056, 16253582.
37. Aronow HD, Steinhubl SR, Brennan DM, Berger PB, Topol EJ, . CREDO Investigators Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2009, 157:369-374. 10.1016/j.ahj.2008.09.011, 19185647, CREDO Investigators.
38. Roy P, Bonello L, Torguson R, de Labriolle A, Lemesle G, Slottow TL, Steinberg DH, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Lindsay J, Waksman R. Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol 2008, 102:1614-1617. 10.1016/j.amjcard.2008.07.063, 19064014.
39. Altman R, Scazziota A, Herrera ML. Principles of antiplatelet therapy. Interventional Cardiovascular Pharmacology 2007, 31-40. UK: Informa Healthcare, Kipshidze N, Fareed J, Moses JW, Serruys PW.
40. Santa-Cruz RA, Steinhubl SR. Clopidogrel: how good is it and how does it work?. Curr Cardiol Rep 2004, 6:264-268. 10.1007/s11886-004-0074-z, 15182601.
41. Altman R, Scazziota A, De Lourdes Herrera M, Gonzalez C. Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation. J Thromb Haemost 2006, 4:2022-2027. 10.1111/j.1538-7836.2006.02088.x, 16961610.
42. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007, 115:2196-2207. 10.1161/CIRCULATIONAHA.106.675991, 17452618.
43. Stone GW. Ischaemia versus bleeding: the art of clinical decision-making. Lancet 2009, 373:695-696. 10.1016/S0140-6736(09)60413-X, 19249613.
44. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, . TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015. 10.1056/NEJMoa0706482, 17982182, TRITON-TIMI 38 Investigators.